Geode Capital Management LLC has recently announced that it has increased stake in Atea Pharmaceuticals Inc. (NASDAQ:AVIR) by 3.67%. After grabbing 1.49 million shares, the institutional investor is now in possession of 52705.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 1.79% having worth around $4.87 million. Moreover, Citadel Advisors LLC increased its share by 0.63 million to have a control over 1.19 million shares.
Atea Pharmaceuticals Inc. (AVIR) concluded trading on 05/25/23 at a closing price of $4.63, with 1.88 million shares of worth about $8.71 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -1.70% during that period and on Thursday the price saw a loss of about -3.74%. Currently the company’s common shares owned by public are about 83.33M shares, out of which, 75.70M shares are available for trading.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Sponsored
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 4 analysts are covering the AVIR stock and their offered price forecasts bring an average price target of $5.33. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $8.00 and could fall to a lowest price of $4.00. The stock’s current price level is -15.75% below of average price target set by the analysts, while a dip to estimated low would result in loss of -15.75% for the stock. However, touching the estimated high of $8.00 would mean a gain of 42.12% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 2 times over the past 12 months. They bought 0 shares in 0 of the transactions. In 2 selling transactions, insiders dumped 41,666 shares.
Fidelity Growth Company Fund, Vanguard Total Stock Market ETF, and Fidelity Series Growth Company Fu are the top 3 mutual funds which are holding stakes in Atea Pharmaceuticals Inc. Fidelity Growth Company Fund is currently holding 2.92 million shares of worth totaling $9.55 million. The company recently came selling 38803.0 shares which brought its stake up to 3.51% of the company’s outstanding shares. Fidelity Series Growth Company Fu, after selling 1.68 million shares, have now control over 2.02% of the stake in the company. It holds 29900.0 shares of worth $5.49 million.
Atea Pharmaceuticals Inc. (NASDAQ: AVIR) started trading at $4.82, above $0.01 from concluding price of the previous day. However, the stock later moved at a day high price of 4.8200, or with a loss of -3.74%. Stock saw a price change of 28.97% in past 5 days and over the past one month there was a price change of 39.88%. Year-to-date (YTD), AVIR shares are showing a performance of -3.74% which decreased to -38.51% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.94 but also hit the highest price of $9.79 during that period. The average intraday trading volume for Atea Pharmaceuticals Inc. shares is 751.36K. The stock is currently trading 27.94% above its 20-day simple moving average (SMA20), while that difference is up 34.15% for SMA50 and it goes to -5.36% lower than SMA200.
Geode Capital Management LLC acquired 1.49 million shares of Atea Pharmaceuticals Inc. having value of about $4.87 million. Data submitted at the U.S SEC by Geode Capital Management LLC revealed that the firm now holds 52705.0 shares in the company valued at close to $244024.15, or have control over 3.67% stake in the company. Atea Pharmaceuticals Inc. (NASDAQ: AVIR) currently have 83.33M outstanding shares and institutions hold larger chunk of about 69.80% of that. Holding of mutual funds in the company is about 28.12% while other institutional holders and individual stake holders have control over 37.23% and 23.64% of the stake respectively.
The stock has a current market capitalization of $374.66M. It has posted earnings per share of -$1.31 in the same period. It has Quick Ratio of 51.20 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for AVIR, volatility over the week remained 7.39% while standing at 5.16% over the month.
Analysts are in expectations that Atea Pharmaceuticals Inc. (AVIR) stock would likely to be making an EPS of -$0.47 in the current quarter, while forecast for next quarter EPS is -$0.53 and it is -$2.84 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.55 which is -$0.42 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.38 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -201.40% while it is estimated to decrease by -33.30% in next year.
Analysts at 4 brokerage firms have issued recommendations for the Atea Pharmaceuticals Inc. (AVIR)’s stock and average of those rates the stock at a “Moderate Buy” and assign it a score of 2.70. Out of those 4 Wall Street analysts, 1 recommended a “Buy” rating, while 2 were in favor recommending the stock as a “Hold” and 1 analyst recommended the stock as “Sell”.
